Walking is a fundamental activity for maintaining health. While numerous studies have assessed how much people with chronic ...

Home-based pulmonary rehabilitation has been slowly gaining momentum for chronic obstructive pulmonary disease (COPD), but ...

For COPD patients, the adage holds true: "the first way to get out of a hole is to quit digging one," said Christopher Mosher ...

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the classic male presentation.

We recently published a list of Jim Cramer Put These 14 Stocks Under the Microscope. In this article, we are going to take a ...

In vivo platelet activation and related pathways may be linked to small airways disease and pulmonary vascular changes in smokers.

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

Background: A limited or absent bronchodilator response is used to classify chronic obstructive pulmonary disease (COPD) and can determine the treatment offered. The reliability of the recommended ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.